[go: up one dir, main page]

WO2010132370A3 - Soluble tlt-1 for the treatment and diagnosis of sepsis - Google Patents

Soluble tlt-1 for the treatment and diagnosis of sepsis Download PDF

Info

Publication number
WO2010132370A3
WO2010132370A3 PCT/US2010/034263 US2010034263W WO2010132370A3 WO 2010132370 A3 WO2010132370 A3 WO 2010132370A3 US 2010034263 W US2010034263 W US 2010034263W WO 2010132370 A3 WO2010132370 A3 WO 2010132370A3
Authority
WO
WIPO (PCT)
Prior art keywords
sepsis
diagnosis
treatment
tlt
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/034263
Other languages
French (fr)
Other versions
WO2010132370A2 (en
WO2010132370A8 (en
Inventor
Daniel W. Mc Vicar
A. Valance Washington
Jessica Morales
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of WO2010132370A2 publication Critical patent/WO2010132370A2/en
Publication of WO2010132370A8 publication Critical patent/WO2010132370A8/en
Publication of WO2010132370A3 publication Critical patent/WO2010132370A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides compositions including sTLT-1 and sTREM-1 polypeptides, the use of such polypeptides in therapeutic methods, and kits including such peptides.
PCT/US2010/034263 2009-05-11 2010-05-10 Soluble tlt-1 for the treatment and diagnosis of sepsis Ceased WO2010132370A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17724209P 2009-05-11 2009-05-11
US61/177,242 2009-05-11

Publications (3)

Publication Number Publication Date
WO2010132370A2 WO2010132370A2 (en) 2010-11-18
WO2010132370A8 WO2010132370A8 (en) 2011-08-11
WO2010132370A3 true WO2010132370A3 (en) 2011-09-29

Family

ID=42985622

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/034263 Ceased WO2010132370A2 (en) 2009-05-11 2010-05-10 Soluble tlt-1 for the treatment and diagnosis of sepsis

Country Status (1)

Country Link
WO (1) WO2010132370A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
DK2555789T3 (en) * 2010-04-08 2020-07-20 Inst Nat Sante Rech Med INHIBITANT PEPTIDES DERIVED FROM TREM-LIKE TRANSCRIPT 1 (TLT-1) AND USES THEREOF
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
EP3456742A1 (en) 2012-02-15 2019-03-20 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
PL2814844T3 (en) 2012-02-15 2017-12-29 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
KR20250110365A (en) 2014-07-17 2025-07-18 노보 노르디스크 에이/에스 Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
US11472877B2 (en) 2016-03-04 2022-10-18 Alector Llc Anti-TREM1 antibodies and methods of use thereof
JOP20190248A1 (en) 2017-04-21 2019-10-20 Amgen Inc Trem2 antigen binding proteins and uses thereof
CR20250022A (en) 2018-04-02 2025-02-25 Bristol Myers Squibb Co Anti-TREM-1 antibodies, nucleic acids, and vectors thereof (Divisional 2020-0450)
BR112021019959A2 (en) 2019-04-17 2022-02-08 Novo Nordisk As Bispecific antibody and pharmaceutical formulation
US20230330222A1 (en) * 2020-05-14 2023-10-19 Ascendo Biotechnology, Inc. Selective targeting of the treml1/md2 interaction by small peptide or protein and its use for vaccine adjuvants
CN113755580B (en) * 2021-09-13 2023-10-27 中国医学科学院阜外医院 Pharmaceutical intervention target for treating and/or relieving lymphedema and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180409A1 (en) * 2003-03-16 2004-09-16 Mcvicar Daniel TLT-1, a novel platelet-associated receptor and uses therefor
US20080131423A1 (en) * 2006-12-04 2008-06-05 Government Of The Us, As Represented By The Secretary, Dept. Of Health And Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies, methods and compositions
WO2009141359A1 (en) * 2008-05-23 2009-11-26 Pronota N.V. New biomarker for diagnosis, prediction and/or prognosis of sepsis and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180409A1 (en) * 2003-03-16 2004-09-16 Mcvicar Daniel TLT-1, a novel platelet-associated receptor and uses therefor
US20080131423A1 (en) * 2006-12-04 2008-06-05 Government Of The Us, As Represented By The Secretary, Dept. Of Health And Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies, methods and compositions
WO2009141359A1 (en) * 2008-05-23 2009-11-26 Pronota N.V. New biomarker for diagnosis, prediction and/or prognosis of sepsis and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FORD J W ET AL: "TREM and TREM-like receptors in inflammation and disease", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 21, no. 1, 1 February 2009 (2009-02-01), pages 38 - 46, XP026104157, ISSN: 0952-7915, [retrieved on 20090221], DOI: DOI:10.1016/J.COI.2009.01.009 *
GATTIS JAMES L ET AL: "The structure of the extracellular domain of triggering receptor expressed on myeloid cells like transcript-1 and evidence for a naturally occurring soluble fragment", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US, vol. 281, no. 19, 27 February 2006 (2006-02-27), pages 13396 - 13403, XP002589901, ISSN: 0021-9258, [retrieved on 20060501], DOI: DOI:10.1074/JBC.M600489200 *
LU YEN-TA ET AL: "Preparation and characterization of monoclonal antibody against protein TREM-like transcript-1 (TLT-1)", HYBRIDOMA, LIEBERT, NEW YORK, NY, US, vol. 25, no. 1, 1 February 2006 (2006-02-01), pages 20 - 26, XP002539976, ISSN: 0272-457X, DOI: DOI:10.1089/HYB.2006.25.20 *
MORALES JESSICA ET AL: "Soluble TLT-1 modulates platelet-endothelial cell interactions and actin polymerization", BLOOD COAGULATION & FIBRINOLYSIS, RAPID COMMUNICATIONS, OXFORD, OXFORD, GB, vol. 21, no. 3, 1 April 2010 (2010-04-01), pages 229 - 236, XP009135455, ISSN: 0957-5235 *
WASHINGTON A VALANCE ET AL: "A TREM family member, TLT-1, is found exclusively in the alpha-granules of megakaryocytes and platelets", BLOOD, vol. 104, no. 4, 15 August 2004 (2004-08-15), pages 1042 - 1047, XP002627253, ISSN: 0006-4971 *
WASHINGTON A VALANCE ET AL: "TREM-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humans", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 119, no. 6, 11 May 2009 (2009-05-11), pages 1489 - 1501, XP002589557, ISSN: 0021-9738, DOI: DOI:10.1172/JC136175 *

Also Published As

Publication number Publication date
WO2010132370A2 (en) 2010-11-18
WO2010132370A8 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
WO2010132370A3 (en) Soluble tlt-1 for the treatment and diagnosis of sepsis
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
WO2011047087A3 (en) Protein detection via nanoreporters
WO2008121767A3 (en) Stitched polypeptides
WO2008104803A3 (en) Proteins
WO2010083347A3 (en) Peptidomimetic macrocycles
WO2011143624A3 (en) Humanized and chimeric monoclonal antibodies to cd47
WO2010083385A3 (en) Compounds for reducing drug resistance and uses thereof
WO2009126292A3 (en) Biologically active peptidomimetic macrocycles
WO2012058393A3 (en) Dkk1 antibodies and methods of use
IL187982A0 (en) Human placental collagen compositions, processes for their preparation, methods of their use and kits comprising the compositions
WO2012054638A3 (en) Nmr systems and methods for the detection of analytes
MX355543B (en) Peptidomimetic macrocycles.
WO2009108860A8 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2012020006A3 (en) Anti-fap antibodies and methods of use
WO2012064792A3 (en) Protein complexes for antigen binding and methods of use
WO2008097561A8 (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2011011797A3 (en) Cytokine compositions and methods of use thereof
LT2315773T (en) Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis
WO2010115118A3 (en) Methods for preparing and using multichaperone-antigen complexes
WO2009150255A3 (en) Markers for predicting response and survival in anti-egfr treated patients
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10720070

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10720070

Country of ref document: EP

Kind code of ref document: A2